{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:28:37Z","timestamp":1789712917606,"version":"4.0.1"},"reference-count":137,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031531","name":"Travere Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031531","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec029\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>IgA nephropathy (IgAN) is an inflammatory kidney disease which, if left untreated, often progresses to kidney failure (KF). This systematic literature review identifies, collates, summarizes, and assesses the quality of clinical trial data describing the efficacy of therapies used for IgAN.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec030\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Ovid Embase, PubMed, CENTRAL, and the Cochrane database of systematic reviews were searched on October 18<jats:sup>th<\/jats:sup>, 2021, and updated on December 12<jats:sup>th<\/jats:sup>, 2023. Electronic searches were supplemented with manual searches of key conferences, clinical trial registries, and bibliography screening. PRISMA and Cochrane guidelines were followed.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec031\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 6710 references were identified (electronic and manual searches), of which 6483 were excluded. This resulted in 254 references reporting 183 studies which met our inclusion criteria. The majority of these IgAN studies (98\/183 studies [60%]) had a non-randomized or single-arm design and\/or a small population size or focused on dietary and traditional medicine, resulting in a high risk of bias and necessitated additional filtering to prioritize larger (n&gt;30) randomized assessment of pharmacological interventions reporting key clinical outcomes. This additional filtering resulted in 76 randomized controlled trials (100 references) selected for narrative synthesis; 60 reported proteinuria outcomes and 18 reported estimated glomerular filtration rate (eGFR) outcomes.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec032\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Until recently, the evidence has been mixed or inconsistent across studies for the efficacy of IgAN treatments in reducing proteinuria or slowing eGFR decline due to a high risk of bias in many included studies. The latest large, phase 3 NefIgArd (NCT03643965) and PROTECT (NCT03762850) clinical trials have demonstrated a meaningful reduction in proteinuria and eGFR decline for patients with IgAN receiving targeted-release formulation budesonide (TRF-B) or sparsentan. Results from other high-quality randomized controlled trials with a follow-up period of at least 2 years are still required to better support advancements in the management of IgAN.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0323530","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T17:58:01Z","timestamp":1749578281000},"page":"e0323530","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1959-0250","authenticated-orcid":true,"given":"Anushya","family":"Jeyabalan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenar D.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bunke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon A.","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.W.","family":"Cork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Bensink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"issue":"1","key":"pone.0323530.ref001","first-page":"1","article-title":"Extracapillary proliferation in IgA nephropathy; recent findings and new ideas","volume":"4","author":"H Nasri","year":"2015","journal-title":"J Nephropathol"},{"issue":"3","key":"pone.0323530.ref002","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ki.2014.86","article-title":"Fatigue in advanced kidney disease","volume":"86","author":"M Artom","year":"2014","journal-title":"Kidney Int"},{"issue":"12","key":"pone.0323530.ref003","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1093\/ndt\/gfh538","article-title":"Subjective and objective physical limitations in high-functioning renal dialysis patients","volume":"19","author":"C Blake","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"pone.0323530.ref004","first-page":"705","article-title":"End-stage renal disease: symptom management and advance care planning","volume":"85","author":"NR O\u2019Connor","year":"2012","journal-title":"Am Fam Physician"},{"key":"pone.0323530.ref005","doi-asserted-by":"crossref","unstructured":"Barratt J, Saleem M, Braddon F, Carroll K, He P, Hendry B. Natural history of IgA nephropathy: analysis of a UK national RaDaR IgA nephropathy cohort. In: 2021.","DOI":"10.1681\/ASN.20213210S1494b"},{"key":"pone.0323530.ref006","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","author":"Group Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work","year":"2021","journal-title":"Kidney Int"},{"key":"pone.0323530.ref007","doi-asserted-by":"crossref","first-page":"715253","DOI":"10.3389\/fphar.2021.715253","article-title":"An Update on Targeted Treatment of IgA Nephropathy: An Autoimmune Perspective","volume":"12","author":"X Huang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"6","key":"pone.0323530.ref008","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1681\/ASN.2006040347","article-title":"IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria","volume":"18","author":"R Coppo","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"pone.0323530.ref009","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1046\/j.1523-1755.2000.00432.x","article-title":"ACEI\/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis","volume":"58","author":"KT Woo","year":"2000","journal-title":"Kidney Int"},{"issue":"10","key":"pone.0323530.ref010","doi-asserted-by":"crossref","DOI":"10.1152\/ajpregu.00425.2015","article-title":"Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease","volume":"310","author":"R Komers","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"6","key":"pone.0323530.ref011","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.ekir.2021.02.018","article-title":"Supportive Management of IgA Nephropathy With Renin-Angiotensin Blockade, the AIIMS Primary IgA Nephropathy Cohort (APPROACH) Study","volume":"6","author":"S Bagchi","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"1","key":"pone.0323530.ref012","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1681\/ASN.2017060713","article-title":"Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy","volume":"29","author":"T Rauen","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"pone.0323530.ref013","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ekir.2017.02.003","article-title":"Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy","volume":"2","author":"Q Cai","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"4","key":"pone.0323530.ref014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ekir.2021.03.868","article-title":"POS-830 nefecon for the treatment of iga nephropathy in patients at risk of progressing to end-stage renal disease: the nefigard phase 3 trial results","volume":"6","author":"J Barratt","year":"2021","journal-title":"Kidney International Reports"},{"key":"pone.0323530.ref015"},{"issue":"2","key":"pone.0323530.ref016","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"J Barratt","year":"2023","journal-title":"Kidney Int"},{"issue":"10405","key":"pone.0323530.ref017","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"R Lafayette","year":"2023","journal-title":"Lancet"},{"issue":"10417","key":"pone.0323530.ref018","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"BH Rovin","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"pone.0323530.ref019","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.ekir.2019.08.007","article-title":"Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial)","volume":"4","author":"J Barratt","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"5","key":"pone.0323530.ref020","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.ekir.2023.02.1086","article-title":"IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study","volume":"8","author":"J Barratt","year":"2023","journal-title":"Kidney Int Rep"},{"key":"pone.0323530.ref021","unstructured":"A study of the effect and safety of sparsentan in the treatment of patients with IgA nephropathy (PROTECT). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03762850."},{"issue":"10388","key":"pone.0323530.ref022","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"HJL Heerspink","year":"2023","journal-title":"Lancet"},{"key":"pone.0323530.ref023","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"key":"pone.0323530.ref024","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022)","author":"J Higgins","year":"2022"},{"key":"pone.0323530.ref025","volume-title":"CRD\u2019s Guidance for Undertaking Systematic Reviews in Health Care 2009","author":"CRD"},{"key":"pone.0323530.ref026","volume-title":"Single technology appraisal: User guide for company evidence submission template","author":"NICE","year":"2015"},{"key":"pone.0323530.ref027","volume-title":"The Newcastle\u2013Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis 2000","author":"G Wells"},{"key":"pone.0323530.ref028","volume-title":"Guidance on the conduct of narrative synthesis in systematic Reviews. A Product from the ESRC Methods Programme. Version 12006","author":"J Popay"},{"key":"pone.0323530.ref029","article-title":"Efficacy and safety of a combination treatment of mycophenolate mofetil and corticosteroid in advanced IgA nephropathy: a multicenter, prospective study","author":"C-Y Jung","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"pone.0323530.ref030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ekir.2019.05.416","article-title":"SUN-021 dual blockade of the renin-angiotensin system in patients with iga nephropathy - insights from the stop-igan trial","volume":"4","author":"D Lennartz","year":"2019","journal-title":"Kidney International Reports"},{"issue":"3","key":"pone.0323530.ref031","doi-asserted-by":"crossref","DOI":"10.1016\/j.ekir.2020.02.419","article-title":"SAT-395 dual blockade of the renin-angiotensin system in patients with iga nephropathy","volume":"5","author":"DP Lennartz","year":"2020","journal-title":"Kidney International Reports"},{"key":"pone.0323530.ref032","article-title":"A phase 2, randomized, double-blind, placebo-controlled trial of telitacicept in patients with iga nephropathy and persistent proteinuria","author":"J-C Lv","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"pone.0323530.ref033","article-title":"Efficacy and Safety of Ravulizumab in a Phase 2 Randomized Controlled Trial in IgA Nephropathy","author":"J Barratt","year":"2023","journal-title":"ASN Kidney week"},{"issue":"3","key":"pone.0323530.ref034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ekir.2023.02.612","article-title":"WCN23-0412 effect of iptacopan on proteinuria and complement biomarkers over time in iga nephropathy","volume":"8","author":"J Barratt","year":"2023","journal-title":"Kidney International Reports"},{"key":"pone.0323530.ref035","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfad063a_3848","article-title":"#3848 origin trial: 24-wk primary analysis of a randomized, double-blind, placebo-controlled ph2b study of atacicept in patients with igan","volume":"38","author":"R Lafayette","year":"2023","journal-title":"Nephrology Dialysis Transplantation"},{"key":"pone.0323530.ref036","doi-asserted-by":"crossref","unstructured":"Barratt J, Maes BD, Lin CJF, Wei X, Barbour S, Phoon RKS, et al. Atacicept 150\u2009mg Reduces Serum Gd-IgA1, a Biomarker Associated with Long-Term Outcomes in IgA Nephropathy (IgAN): 36W Results from the Ph2b ORIGIN Study. ASN Kidney week 2023.","DOI":"10.1681\/ASN.20233411S1974c"},{"key":"pone.0323530.ref037","article-title":"Efficacy and safety of reduced-dose oral methylprednisone in IgA nephropathy: The testing trial","author":"D Kim","year":"2022","journal-title":"Nephrol"},{"key":"pone.0323530.ref038","doi-asserted-by":"crossref","unstructured":"Kim D, Lv J, Hladunewich M, Jha V, Hooi LS, Monaghan H, et al. Efficacy and safety of reduced-dose oral methylprednisone in IgA nephropathy: The testing trial. 2023.","DOI":"10.1016\/j.ekir.2023.02.118"},{"issue":"2","key":"pone.0323530.ref039","doi-asserted-by":"crossref","DOI":"10.1016\/j.ekir.2022.01.453","article-title":"POS-427 leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labelled and controlled trial","volume":"7","author":"Z ZHANG","year":"2022","journal-title":"Kidney International Reports"},{"issue":"5","key":"pone.0323530.ref040","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00467-018-4099-8","article-title":"Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study)","volume":"34","author":"Y Shima","year":"2019","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"pone.0323530.ref041","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1159\/000489914","article-title":"Add-On Effect of Angiotensin Receptor Blockade (Candesartan) on Clinical Remission in Active IgA Nephropathy Patients Treated with Steroid Pulse Therapy and Tonsillectomy: a Randomized, Parallel-Group Comparison Trial","volume":"43","author":"K Kohagura","year":"2018","journal-title":"Kidney Blood Press Res"},{"issue":"2","key":"pone.0323530.ref042","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3904\/kjim.2014.266","article-title":"Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial","volume":"31","author":"Y-I Jo","year":"2016","journal-title":"Korean J Intern Med"},{"issue":"5","key":"pone.0323530.ref043","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","article-title":"Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study","volume":"47","author":"PK-T Li","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"pone.0323530.ref044","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1291\/hypres.27.963","article-title":"Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy","volume":"27","author":"Y Horita","year":"2004","journal-title":"Hypertens Res"},{"issue":"5","key":"pone.0323530.ref045","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1440-1797.2006.00665.x","article-title":"Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy","volume":"11","author":"Y Horita","year":"2006","journal-title":"Nephrology (Carlton)"},{"issue":"3","key":"pone.0323530.ref046","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/qjmed\/hci036","article-title":"Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation","volume":"98","author":"Y Kanno","year":"2005","journal-title":"QJM"},{"issue":"3","key":"pone.0323530.ref047","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3349\/ymj.2003.44.3.463","article-title":"Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy","volume":"44","author":"MJ Kim","year":"2003","journal-title":"Yonsei Med J"},{"issue":"6","key":"pone.0323530.ref048","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/ndt\/gfg090","article-title":"Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy","volume":"18","author":"HC Park","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"pone.0323530.ref049","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","article-title":"Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial","volume":"14","author":"M Praga","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"pone.0323530.ref050","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000013619","article-title":"Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy","volume":"20","author":"T Nakamura","year":"2000","journal-title":"Am J Nephrol"},{"issue":"3","key":"pone.0323530.ref051","first-page":"265","article-title":"ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study","volume":"9","author":"G Maschio","year":"1994","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"pone.0323530.ref052","doi-asserted-by":"crossref","first-page":"452","DOI":"10.23876\/j.krcp.21.146","article-title":"A multicenter, randomized, open-label, comparative, phase IV study to evaluate the efficacy and safety of combined treatment with mycophenolate mofetil and corticosteroids in advanced immunoglobulin A nephropathy","volume":"41","author":"SY Han","year":"2022","journal-title":"Kidney Res Clin Pract"},{"issue":"1","key":"pone.0323530.ref053","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1080\/0886022X.2021.1963775","article-title":"Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial","volume":"43","author":"Z Ni","year":"2021","journal-title":"Ren Fail"},{"issue":"3","key":"pone.0323530.ref054","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria","volume":"8","author":"J Lv","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"6","key":"pone.0323530.ref055","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s40620-020-00836-8","article-title":"Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy","volume":"33","author":"DP Lennartz","year":"2020","journal-title":"J Nephrol"},{"issue":"23","key":"pone.0323530.ref056","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive Supportive Care plus Immunosuppression in IgA Nephropathy","volume":"373","author":"T Rauen","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0323530.ref057","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial","volume":"74","author":"L-J Liu","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"10084","key":"pone.0323530.ref058","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"BC Fellstr\u00f6m","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"pone.0323530.ref059","doi-asserted-by":"crossref","first-page":"159","DOI":"10.23876\/j.krcp.2017.36.2.159","article-title":"Efficacy and safety of adding mizoribine to standard treatment in patients with immunoglobulin A nephropathy: A randomized controlled trial","volume":"36","author":"K Hirai","year":"2017","journal-title":"Kidney Res Clin Pract"},{"issue":"6","key":"pone.0323530.ref060","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial","volume":"69","author":"J-H Hou","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"pone.0323530.ref061","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction","volume":"28","author":"RA Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"pone.0323530.ref062","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial","volume":"318","author":"J Lv","year":"2017","journal-title":"JAMA"},{"issue":"19","key":"pone.0323530.ref063","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial","volume":"327","author":"J Lv","year":"2022","journal-title":"JAMA"},{"issue":"29","key":"pone.0323530.ref064","doi-asserted-by":"crossref","first-page":"48375","DOI":"10.18632\/oncotarget.16468","article-title":"Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy","volume":"8","author":"L Min","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"pone.0323530.ref065","article-title":"Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: A 5-year follow-up study","volume":"12","author":"M-Y Yu","year":"2017","journal-title":"PLoS One"},{"issue":"8","key":"pone.0323530.ref066","article-title":"Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy","volume":"8","author":"Y-C Kim","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"pone.0323530.ref067","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1007\/s10157-016-1226-3","article-title":"Comparison of steroid-pulse therapy and combined with mizoribine in IgA nephropathy: a randomized controlled trial","volume":"20","author":"K Masutani","year":"2016","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"pone.0323530.ref068","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"RJ Hogg","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"pone.0323530.ref069","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2169\/internalmedicine.53.1136","article-title":"Comparison of glucocorticoids alone and combined with cyclosporine a in patients with IgA nephropathy: a prospective randomized controlled trial","volume":"53","author":"H Liu","year":"2014","journal-title":"Intern Med"},{"issue":"2","key":"pone.0323530.ref070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.5414\/CP201887","article-title":"Treatment of severe IgA nephropathy: mycophenolate mofetil\/prednisone compared to cyclophosphamide\/prednisone","volume":"52","author":"X Liu","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"8","key":"pone.0323530.ref071","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5414\/CPP48509","article-title":"Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome","volume":"48","author":"XW Liu","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"pone.0323530.ref072","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","article-title":"Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy","volume":"68","author":"S Tang","year":"2005","journal-title":"Kidney Int"},{"issue":"6","key":"pone.0323530.ref073","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ki.2009.499","article-title":"Long-term study of mycophenolate mofetil treatment in IgA nephropathy","volume":"77","author":"SCW Tang","year":"2010","journal-title":"Kidney Int"},{"issue":"1","key":"pone.0323530.ref074","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","article-title":"Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial","volume":"53","author":"J Lv","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"pone.0323530.ref075","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","article-title":"Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy","volume":"24","author":"C Manno","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"pone.0323530.ref076","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s10157-008-0036-7","article-title":"Clinical assessment of low-dose steroid therapy for patients with IgA nephropathy: a prospective study in a single center","volume":"12","author":"M Koike","year":"2008","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"pone.0323530.ref077","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1440-1797.2006.00547.x","article-title":"Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy","volume":"11","author":"T Lou","year":"2006","journal-title":"Nephrology (Carlton)"},{"issue":"10","key":"pone.0323530.ref078","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","article-title":"Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial","volume":"20","author":"G Frisch","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"pone.0323530.ref079","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"BD Maes","year":"2004","journal-title":"Kidney Int"},{"issue":"1","key":"pone.0323530.ref080","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial","volume":"15","author":"C Pozzi","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"9156","key":"pone.0323530.ref081","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: a randomised controlled trial","volume":"353","author":"C Pozzi","year":"1999","journal-title":"Lancet"},{"issue":"5","key":"pone.0323530.ref082","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0272-6386(03)00194-X","article-title":"Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy","volume":"41","author":"R Katafuchi","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"pone.0323530.ref083","doi-asserted-by":"crossref","DOI":"10.1046\/j.1440-1797.1999.00097.x","article-title":"A randomized prospective control study of low dose prednisolone therapy for IgA nephropathy: Its usefulness and limitations","volume":"5","author":"R Katafuchi","year":"1999","journal-title":"Nephrology"},{"issue":"1","key":"pone.0323530.ref084","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1681\/ASN.V131142","article-title":"Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy","volume":"13","author":"FW Ballardie","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"pone.0323530.ref085","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1081\/JDI-100104732","article-title":"Role of proteinuria reduction in the progression of IgA nephropathy","volume":"23","author":"F Locatelli","year":"2001","journal-title":"Ren Fail"},{"issue":"4","key":"pone.0323530.ref086","first-page":"174","article-title":"Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial","volume":"26","author":"KN Lai","year":"1986","journal-title":"Clin Nephrol"},{"key":"pone.0323530.ref087","unstructured":"www.clinicaltrials.gov. Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation. Completed. NCT03373461."},{"issue":"10","key":"pone.0323530.ref088","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1007\/s00467-023-05919-9","article-title":"Corticosteroids in the treatment of IgA nephropathy: lessons from the TESTING trial","volume":"38","author":"Y Zhang","year":"2023","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"pone.0323530.ref089","article-title":"Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial","volume":"6","author":"FF Hou","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"pone.0323530.ref090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41598-021-03691-0","article-title":"Effect of pulsed intravenous methylprednisolone with alternative low-dose prednisone on high-risk IgA nephropathy: a 18-month prospective clinical trial","volume":"12","author":"Y Li","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0323530.ref091","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12882-022-02661-6","article-title":"The effectiveness and safety of corticosteroid therapy for IgA nephropathy with crescents: a prospective, randomized, controlled study","volume":"23","author":"M Liang","year":"2022","journal-title":"BMC Nephrol"},{"issue":"1","key":"pone.0323530.ref092","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12882-023-03106-4","article-title":"The clinical efficacy of fluticasone propionate combined with ACEI\/ARB in the treatment of immunoglobulin A nephropathy","volume":"24","author":"L Sun","year":"2023","journal-title":"BMC Nephrol"},{"key":"pone.0323530.ref093"},{"issue":"7","key":"pone.0323530.ref094","doi-asserted-by":"crossref","DOI":"10.1016\/j.ekir.2019.05.431","article-title":"SUN-036 spleen tyrosine kinase (syk) inhibition in iga nephropathy: a global, phase ii, randomised placebo-controlled trial of fostamatinib","volume":"4","author":"F Tam WK","year":"2019","journal-title":"Kidney International Reports"},{"key":"pone.0323530.ref095","unstructured":"www.clinicaltrials.gov. Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy. Completed. NCT02112838."},{"issue":"12","key":"pone.0323530.ref096","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1016\/j.ekir.2023.09.024","article-title":"Randomized Trial on the Effect of an Oral Spleen Tyrosine Kinase Inhibitor in the Treatment of IgA Nephropathy","volume":"8","author":"FWK Tam","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"1","key":"pone.0323530.ref097","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy","volume":"390","author":"M Mathur","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0323530.ref098","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"DC Wheeler","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"pone.0323530.ref099","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/nep.12177","article-title":"Probucol combined with valsartan in immunoglobulin A nephropathy: a multi-centre, open labelled, randomized controlled study","volume":"19","author":"Z Ye","year":"2014","journal-title":"Nephrology (Carlton)"},{"issue":"3","key":"pone.0323530.ref100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000331453","article-title":"Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial","volume":"35","author":"Y Shi","year":"2012","journal-title":"Kidney Blood Press Res"},{"key":"pone.0323530.ref101","first-page":"645","article-title":"Beneficial effect of pioglitazone in proteinuric igAnephropathy with concomitant acei\/arb treatment","volume":"3","author":"T Kanjanabuch","year":"2009","journal-title":"Asian Biomedicine"},{"issue":"4","key":"pone.0323530.ref102","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/ndt\/gfh069","article-title":"Effects of co-administration of urokinase and benazepril on severe IgA nephropathy","volume":"19","author":"X Chen","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"pone.0323530.ref103","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0272-6386(12)80511-7","article-title":"Sodium cromoglycate therapy in IgA nephropathy: a preliminary short-term trial","volume":"15","author":"M Sato","year":"1990","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"pone.0323530.ref104","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00467-018-4011-6","article-title":"Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT","volume":"33","author":"Y Shima","year":"2018","journal-title":"Pediatr Nephrol"},{"issue":"16","key":"pone.0323530.ref105","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.4103\/0366-6999.187848","article-title":"Efficacy of Leflunomide, Telmisartan, and Clopidogrel for Immunoglobulin A Nephropathy: A Randomized Controlled Trial","volume":"129","author":"J Wu","year":"2016","journal-title":"Chinese Medical Journal"},{"issue":"2","key":"pone.0323530.ref106","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/nep.12359","article-title":"Valsartan combined with clopidogrel and\/or leflunomide for the treatment of progressive immunoglobulin A nephropathy","volume":"20","author":"G Cheng","year":"2015","journal-title":"Nephrology (Carlton)"},{"issue":"5","key":"pone.0323530.ref107","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/MAJ.0b013e318207e02d","article-title":"Efficacy and safety of mizoribine combined with losartan in the treatment of IgA nephropathy: a multicenter, randomized, controlled study","volume":"341","author":"Y Xie","year":"2011","journal-title":"Am J Med Sci"},{"issue":"6","key":"pone.0323530.ref108","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2215\/CJN.08630910","article-title":"Long-term results of a randomized controlled trial in childhood IgA nephropathy","volume":"6","author":"K Kamei","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"pone.0323530.ref109","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2215\/CJN.01120905","article-title":"Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial","volume":"1","author":"N Yoshikawa","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"pone.0323530.ref110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1681\/ASN.V101101","article-title":"A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group","volume":"10","author":"N Yoshikawa","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"pone.0323530.ref111","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1440-1797.1998.d01-12.x","article-title":"A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy","volume":"4","author":"IK CHENG","year":"1998","journal-title":"Nephrology"},{"issue":"2","key":"pone.0323530.ref112","first-page":"56","article-title":"Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis","volume":"27","author":"KT Woo","year":"1987","journal-title":"Clin Nephrol"},{"issue":"2","key":"pone.0323530.ref113","first-page":"60","article-title":"Effects of triple therapy in IgA nephritis: a follow-up study 5 years later","volume":"36","author":"KT Woo","year":"1991","journal-title":"Clin Nephrol"},{"issue":"3","key":"pone.0323530.ref114","first-page":"103","article-title":"The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial","volume":"34","author":"RG Walker","year":"1990","journal-title":"Clin Nephrol"},{"issue":"4","key":"pone.0323530.ref115","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/08860220701260511","article-title":"Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy","volume":"29","author":"Y Horita","year":"2007","journal-title":"Ren Fail"},{"issue":"6","key":"pone.0323530.ref116","doi-asserted-by":"crossref","first-page":"617","DOI":"10.5414\/CNP71617","article-title":"Beneficial effects of high-dose losartan in IgA nephritis","volume":"71","author":"K-T Woo","year":"2009","journal-title":"Clin Nephrol"},{"issue":"3","key":"pone.0323530.ref117","first-page":"227","article-title":"Disease progression, response to ACEI\/ATRA therapy and influence of ACE gene in IgA nephritis","volume":"4","author":"KT Woo","year":"2007","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"pone.0323530.ref118","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.amjmed.2012.06.028","article-title":"Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor","volume":"126","author":"PK-T Li","year":"2013","journal-title":"Am J Med"},{"issue":"9","key":"pone.0323530.ref119","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1291\/hypres.31.1711","article-title":"Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy","volume":"31","author":"A Shimizu","year":"2008","journal-title":"Hypertens Res"},{"issue":"10","key":"pone.0323530.ref120","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1681\/ASN.2010010117","article-title":"Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy","volume":"21","author":"C Pozzi","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"pone.0323530.ref121","doi-asserted-by":"crossref","first-page":"86","DOI":"10.5301\/jn.5000110","article-title":"IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine","volume":"26","author":"C Pozzi","year":"2013","journal-title":"J Nephrol"},{"issue":"6","key":"pone.0323530.ref122","doi-asserted-by":"crossref","first-page":"355","DOI":"10.21037\/atm-22-1028","article-title":"Immunosuppressants or corticosteroids compared with supportive therapy: a systematic review and meta-analysis on the efficacy and safety for IgA nephropathy treatment","volume":"10","author":"Q Feng","year":"2022","journal-title":"Ann Transl Med"},{"issue":"3","key":"pone.0323530.ref123","article-title":"Immunosuppressive agents for treating IgA nephropathy","volume":"3","author":"P Natale","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"pone.0323530.ref124","article-title":"Non-immunosuppressive treatment for IgA nephropathy","author":"S Reid","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"pone.0323530.ref125","article-title":"Antiplatelet agents for chronic kidney disease","volume":"2","author":"P Natale","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"pone.0323530.ref126","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"EY Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0323530.ref127","unstructured":"www.clinicaltrials.gov. Rituximab and RASi in Patients With IgAN (RITA). Ongoing. NCT04525729."},{"key":"pone.0323530.ref128","unstructured":"www.clinicaltrials.gov. Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN). Ongoing. NCT04684745."},{"key":"pone.0323530.ref129","unstructured":"www.clinicaltrials.gov. Atacicept in Subjects With IgA Nephropathy (ORIGIN). Ongoing. NCT04716231."},{"issue":"9","key":"pone.0323530.ref130","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1681\/ASN.2015080856","article-title":"IgA1 Protease Treatment Reverses Mesangial Deposits and Hematuria in a Model of IgA Nephropathy","volume":"27","author":"SM Lechner","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"pone.0323530.ref131","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1681\/ASN.2018101017","article-title":"Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study","volume":"30","author":"S Jarrick","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"pone.0323530.ref132","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy","volume":"14","author":"A Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"pone.0323530.ref133","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1681\/ASN.2020030349","article-title":"Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy","volume":"32","author":"M Canney","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"pone.0323530.ref134","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/ki.2013.210","article-title":"Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease","volume":"84","author":"SJ Barbour","year":"2013","journal-title":"Kidney Int"},{"issue":"1","key":"pone.0323530.ref135","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"H Zhang","year":"2024","journal-title":"Kidney Int"},{"issue":"12","key":"pone.0323530.ref136","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003474","article-title":"Cardiovascular health metrics from mid- to late-life and risk of dementia: a population-based cohort study in Finland","volume":"17","author":"Y Liang","year":"2020","journal-title":"PLoS Med"},{"issue":"3","key":"pone.0323530.ref137","article-title":"WCN23-0069 efficacy and safety of reduced-dose oral methylprednisolone in iga nephropathy: the testing trial","volume":"8","author":"D KIM","year":"2023","journal-title":"Kidney International Reports"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0323530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T17:58:35Z","timestamp":1749578315000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0323530"}},"subtitle":[],"editor":[{"given":"Rajendra","family":"Bhimma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":137,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0323530","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]}}}